47. Buerger disease Clinical trials / Disease details
Clinical trials : 9 / Drugs : 13 - (DrugBank : 7) / Drug target genes : 6 - Drug target pathways : 15
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04914247 (ClinicalTrials.gov) | June 15, 2021 | 31/5/2021 | Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease | Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease | Non-healing Wound;Thromboangiitis Obliterans | Drug: Selexipag | Actelion | NULL | Available | NULL |